Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb541 in Advanced Solid Tumors

NCT06276491 is registered in ClinicalTrials.gov with Xencor, Inc. as lead sponsor.

NCT NCT06276491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06276491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb541 in Advanced Solid Tumors
Lead sponsor
Xencor, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
April 4, 2024
Completion date
December 31, 2028
Enrollment
282 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer, germ cell tumor, ovarian cancer, ovarian germ cell tumor, testicular germ cell tumor